medigraphic.com
Centro de Investigaciones Regionales Dr. Hideyo Noguchi, Universidad Autónoma de Yucatán

2011, Number 1

<< Back Next >>

Rev Biomed 2011; 22 (1)

Oxidative damage and antioxidant defence markers in chronic hepatitis C patient who are non-responders to PEG-IFN-α:2b plus ribavirin based therapy

Riverón-Forment G, Vilar-Gómez E, Calderín-Sollet Z, Martínez-Pérez Y, Pérez-Sieres N, Martínez-Bonne O, Valdés-Ramos L

Language: Spanish
References: 33
Page: 11-19
PDF size: 110.53 Kb.


ABSTRACT

Introduction. Oxidative stress may be a prominent factor in the induction and progression of Chronic Hepatitis C (CHC). However, there are few reports that evaluate these markers in non-responder patients.
Objective. The aim of this study was to determine some redox status markers in patients with CHC, who respond poorly to conventional therapy.
Materials nd Methods. We performed a crosssectional descriptive study. The sample consisted of 27 patients with CHC of both sexes, treated at the National Institute of Gastroenterology, in the period between October 2008 and May 2009, aged between 26 and 64 years. A reference population of 24 apparently healthy individuals of both sexes in the same age range of the study group were also tested. Samples were evaluated for markers of oxidative damage to lipids and proteins, malonildialdehyde, and advanced oxidation products of proteins. We also determined the activities of antioxidant enzymes: Cu-Zn superoxide dismutase, catalase, glutathione peroxidase, and glutathione reductase.
Results. Our results showed that oxidative damage is higher in CHC patients who respond poorly to conventional antiviral therapy in comparison with the control group. In addition, we found an increase of antioxidant activity of evaluated enzymes in one group of patients.
Conclusions. These data demonstrate that oxidative damage and impairment of antioxidant defences was occurring in patients with chronic hepatitis C who respond poorly to standard therapy.


REFERENCES

  1. Harman D. Free radical theory of aging: an update: increasing the functional life span. Ann N Y Acad Sci 2006; 1067:10-21.

  2. Mc Cord JM, Fridovich I. Superoxide dismutase: an enzymic function for erythrocuprein (hemocuprein). J Biol Chem 1969; 244:6049-55.

  3. Novo E, Parola M. Redox mechanisms in hepatic chronic wound healing and fibrogenesis. Fibrogenesis Tissue Repair 2008; 1:5.

  4. Matés JM, Pérez-Gómez C, Nuńez de Castro I. Antioxidant Enzymes and Human Diseases. Clin Biochem 1999; 32:595-603.

  5. National Institute of Health consensus statement on management of hepatitis C: 2002. NIH Consens State Sci Statements 2002; 19:1-46.

  6. Arús E. Historia natural de la infección por el virus de la Hepatitis C. En: Hernádez JC, Samada M, editores. Hepatología 2006. Ciudad de la Habana: Editorial CIMEQ; 2006. p15.

  7. Stauber RE, Stadlbauer V. Novel approaches for therapy of chronic hepatitis C. J Clin Virol 2006; 36:87-94.

  8. Witko-Sarsat V, Friedlander M, Nguyen Khoa T, Capeillére-Blandin C, Nguyen AT, Canteloup S, et al. Advanced Oxidation Protein Products as Novel Mediators of Inflammation and Monocyte Activation in Chronic Renal Failure. J Immunol 1998; 161:2524-32.

  9. Fulbert JC, Succari M, Cals MJ. Semi-automated Assay of Erythrocite Cu-Zn Superoxide Dismutase Activity. Clin Biochem 1992; 25:115-9.

  10. Groenbaek K, Friis H, Hansen M, Ring-Larsena H, Krarup HB, The effect of antioxidant supplementation on hepatitis C viral load, transaminases and oxidative status: a randomized trial among chronic hepatitis C virus-infected patients. Eur J Gastroenterol Hepatol 2006; 18:985–9.

  11. Mahmood S, Kawanaka M, Kamei A, Izumi A, Nakata K, Niiyama G, et al. Immunohistochemi-cal evaluation of oxidative stress markers in chronic hepatitis C. Antioxid Redox Signal 2004; 6:19-24.

  12. De María N, Colantoni A, Fagiuoli S, Liu GJ, Rogers BK, Farinati F, et al. Association between reactive oxygen species activity in chronic hepatitis C and disease. Free Radic Biol Med. 1996; 21:291-5.

  13. Boya P. Pena A, Beloqui O, Larrea E, Conchillo M, Castelruiz Y, et al. Antioxidant status and glutathione metabolism in peripheral blood mononuclear cells from patients with chronic hepatitis. J Clin Hepatol 1999; 31:808-14.

  14. Sögergren E. Lipid Peroxidation in vivo. Evaluation and Application of Methods for Measurements [dissertation]. Uppsala: Uppsala Univ.; 2000.

  15. Paradis V, Mathurin P, Kollinger M, Imbert-Bismut F, Charlotte F, Piton A, et al. In situ detection of lipid peroxidation in chronic hepatitis C: correlation with pathological features. J Clin Pathol 1997; 50:401-6.

  16. Romero FJ, Bosch-Morell F, Romero MJ, Jareńo EJ, Romero B, Marín N, et al. Lipid Peroxidation Products and Antioxidants in Human Disease. Environ Health Perspect 1998; 106:1229-34.

  17. Levent G, Ali A, Ahmet A, Polat EC, Aytaç C, Ayşe E, Ahmet S. Oxidative stress and antioxidant defense in patients with chronic hepatitis C patients before and after pegylated interferon alfa-2b plus ribavirin therapy. J Transl Med 2006; 4:25.

  18. Witko-Sarsat V, Friedlander M, Capeillére-Blandin C, Nguyen-Khoa T, Nguyen AT, Zingraff J, et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996; 49:1304-13.

  19. Shacter, E. Quantification and significance of protein oxidation in biological samples. Drug Metab Rev 2000;32:307-26.

  20. Lazárová M, Stejskal, Laéóák B, Václavík J, Adamovská S, Ochmanová R, et al. The entioxidant acetylcysteine reduces oxidatives stress by decreasing level of AOPPs. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2004; 148:131-3

  21. Selmeci L, Seres L, Antal M, Lukács J, Regöly-Mérey A, Acsády G. Advanced oxidation protein products (AOPP) for monitoring oxidative stress in critically ill patients: a simple, fast and inexpensive automated technique. Clin Chem Lab Med 2005; 43:294–7.

  22. Chang ML, Yeh CT, Lin DY, Ho YP, Hsu CM, Bissell DM. Hepatic inflammation mediated by hepatitis C vi rus core protein is ameliorated by blocking complement activation. BMC Med Genomics 2009; 2:51.

  23. Zeremski M, Petrovic LM, Chiriboga L, Brown QB, Yee HT, Kinkhabwala M, et al. Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C. Hepatology 2008; 48:1440-50.

  24. Melhem A, Stern M, Shibolet O, Israeli E, Ackerman Z, Pappo O, et al. Treatment of chronic hepatitis C virus infection via antioxidants. Results of a phase I clinical trial. J Clin Gastroenterol 2005; 39:737-42.

  25. Ko WS, Guo CH, Yeh MS, Lin LY, Hsu GS, Chen PC, et al. Blood micronutrient, oxidative stress, and viral load in patients with chronic hepatitis C. World J Gastroenterol 2005; 11:4697-702.

  26. Sezer S, Tutal E, Aldemir D, Türkoglu S, Demirel OU, Afsar B, et al. Hepatitis C infection in hemodialysis patients: Protective against oxidative stress?. Transplant Proc 2006; 38:406-10.

  27. Irshad M, Chaudhuri PS, Joshi YK. Superoxide dismutase and total antioxidant levels in various forms of liver diseases. Hepatol Res 2002; 23:178-84.

  28. Castellano-Higuera A, González-Reimers E, Alemán-Valls MR, Abreu--González P, Santolaria-Fernández F, Vega-Prieto de la M, et al. Cytokines and lipid peroxidation in alcoholics with chronic hepatitis C virus infection. Alcohol Alcohol 2008;43:137-42.

  29. Karabulut AB, Sonmez E, Bayindir Y, Gözükara E. A Comparison of erythrocyte superoxide dismutase and catalase activity in patients with hepatitis C infection. Turk J Med Sci 2002; 32:313-16.

  30. Chaudiére J, Ferrari-Iliou R. Intracellular antioxidants: from chemical to biochemical mechanisms. Food Chem Toxicol 1999; 37:949-62.

  31. Dröge W. Free Radicals in the Physiological Control of Cell Function. Physiol Rev 2002; 82:47–95.




2020     |     www.medigraphic.com